EPISODE · Jul 14, 2017 · 29 MIN
The Onco'Zine Brief: Nano-Pulse Stimulation (NPS)
from The Onco'Zine Brief with Peter Hofland · host Peter Hofland
In this episode of The OncoZine Brief host Peter Hofland interviews Darrin Uecker and Richard Nuccitelli of Pulse Biosciences. The team at Pulse Biosciences has developed a technology is called Nano-pulse Stimulation, or NPS. This novel technology delivers ultra-short nanosecond pulses to stimulate cellular responses in targeted tissue. These pulses induce cells to die in a natural way. Preclinical studies indicate that NPS can stimulate the adaptive immune response, commonly known as immunogenic cell death. The new technology thus engages the immune system to clear away damaged, diseased, or aged cells and recruit cancer-attacking T cells to the tumor site. Host Peter Hofland asks Darrin Uecker and Richard Nuccitelli about the new technology, its history and how this may benefit patients. For more information visit The Onco'Zine Brief at http://www.oncozine.com
What this episode covers
In this episode of The OncoZine Brief host Peter Hofland interviews Darrin Uecker and Richard Nuccitelli of Pulse Biosciences. The team at Pulse Biosciences has developed a technology is called Nano-pulse Stimulation, or NPS. This novel technology delivers ultra-short nanosecond pulses to stimulate cellular responses in targeted tissue. These pulses induce cells to die in a natural way. Preclinical studies indicate that NPS can stimulate the adaptive immune response, commonly known as immunogenic cell death. The new technology thus engages the immune system to clear away damaged, diseased, or aged cells and recruit cancer-attacking T cells to the tumor site. Host Peter Hofland asks Darrin Uecker and Richard Nuccitelli about the new technology, its history and how this may benefit patients. For more information visit The Onco'Zine Brief at http://www.oncozine.com
NOW PLAYING
The Onco'Zine Brief: Nano-Pulse Stimulation (NPS)
No transcript for this episode yet
Similar Episodes
Mar 26, 2026 ·1m
Mar 19, 2026 ·34m
Feb 18, 2026 ·11m
Feb 11, 2026 ·45m